Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × telitacicept × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

pembrolizumab 153 Carboplatin 126 Cisplatin 80 Paclitaxel 76 Gemcitabine 76 Bevacizumab 70 Pemetrexed 60 Docetaxel 51 Nivolumab 48 Oxaliplatin 47 atezolizumab 46 Cyclophosphamide 44 Dexamethasone 41 Fulvestrant 39 Fluorouracil 38 130-nm albumin-bound paclitaxel 37 durvalumab 33 Prednisone 32 Leucovorin 31 Cetuximab 31 Capecitabine 31 Rituximab 30 Lenalidomide 29 Injections 27 fludarabine 25 Doxorubicin 25 ribociclib 24 Letrozole 24 venetoclax 23 daratumumab 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07249632 2026-04-09

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

RemeGen Co., Ltd.

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡